Trial Profile
A 8-Week, Open-Label, Phase 1 Study To Evaluate Pharmacokinetics, Pharmacodynamics, Safety And Tolerability Of Atorvastatin In Children And Adolescents With Heterozygous Familial Hypercholesterolemia
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Atorvastatin (Primary)
- Indications Hyperlipoproteinaemia type IIa
- Focus Pharmacokinetics
- Sponsors Pfizer
- 20 Mar 2012 This trial is not authorised in Netherlands.
- 20 Mar 2012 Planned number of patients changed from 36 to 39 as reported by European Clinical Trials Database.
- 05 Jun 2009 Actual patient number (39) and actual end date (May 2009) added as reported by ClinicalTrials.gov.